Hemodialysis membrane biocompatibility - Does it matter?

Scandinavian Journal of Urology and Nephrology

Volumn 33, Issue 2, 1999, Pages 83-88

  Jacobson, Stefan H ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CELLULOSE; CELLULOSE ACETATE; CELLULOSE DIACETATE; CELLULOSE TRIACETATE; ERYTHROPOIETIN; HEMOPHAN; POLY(METHYL METHACRYLATE); POLYACRYLONITRILE; POLYSULFONE; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; AMYLOIDOSIS; ANEMIA; ARTIFICIAL MEMBRANE; ATHEROSCLEROSIS; BIOCOMPATIBILITY; CANCER RISK; ECONOMIC ASPECT; HEMODIALYSIS; KIDNEY FUNCTION; LIPID METABOLISM; NUTRITION; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; TECHNOLOGY;

AMYLOIDOSIS; ANEMIA; ARTERIOSCLEROSIS; BIOCOMPATIBLE MATERIALS; HUMANS; INFECTION; KIDNEY FAILURE, ACUTE; MEMBRANES, ARTIFICIAL; NUTRITION DISORDERS; PERMEABILITY; RENAL DIALYSIS;

EID: 0032805190     PISSN: 00365599     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655999750016032     Document Type: Review

References (26)

1. Schiffl H, Lang SM, König A, Strasser T, Haider MC, Held E. Biocompatible membranes in acute renal failure: prospective case-controlled study. Lancet 1994; 344: 570-572.
2. Hakim RM, Wingard RL, Parker RA. Effect of the dialysis membrane in the treatment of patients with acute renal failure. N Engl J Med 1994; 331: 1338-1342.
3. Himmelfarb J, Tolkoff Rubin N, Chandran P, Parker RA, Wingard RL, Hakim R. A multicenter comparison of dialysis membranes in the treatment of acute renal failure requiring dialysis. J Am Soc Nephrol 1998; 9: 257-266.
4. Hartmann J, Fricke H, Schiffl H. Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis. Am J Kidney Dis 1997; 30: 366-373.
5. McCarthy JT, Jenson BM, Squillace DP, Williams AW. Improved preservation of residual renal function in chronic hemodialysis patients using polysulfone dialysers. Am J Kidney Dis 1997; 29: 576-583.
6. Caramelo C, Alcázar R, Gallar P, Teruel JL, Velo M, Ortega O, et al. Choice of dialysis membrane does not influence the outcome of residual renal function in haemodialysis patients. Nephrol Dial Transplant 1994; 9: 675-677.
7. Bergamo Collaborative Dialysis Study Group. Acute intradialytic well-being: results of a clinical trial comparing polysulfone with cuprophane. Kidney Int 1991; 40: 714-719.
8. Collins DM, Lambert MB, Tannenbaum JS, Oliverio M, Schwab SJ. Tolerance of hemodialysis: a randomized prospective trial of high-flux versus conventional high-efficiency hemodialysis. J Am Soc Nephrol 1993; 4: 148-154.
9. Skroeder NR, Jacobson SH, Lins L-E, Kjellstrand CM. Acute symptoms during and between hemodialysis: the relative role of speed, duration and biocompatibility of dialysis. Artif Organs 1994; 18: 880-887.
10. Vanholder R, Ringoir S, Dhondt A, Hakim R. Phagocytosis in uremic and hemodialysis patients: a prospective and cross-sectional study. Kidney Int 1991; 39: 320-327.
11. Hornberger JC, Chernew M, Petersen J, Garber AM. A multivariate analysis of mortality and hospital admissions with high-flux dialysis. J Am Soc Nephrol 1992; 3: 1227-1237.
12. van Ypersele de Strihou C, Jadoul M, Malghem J, Maldague B, Jamart J. and the Working Party on Dialysis Amyloidosis. Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. Kidney Int 1991; 39: 1012-1019.
13. 2-microglobulin levels in chronic hemodialysis patients. J Am Soc Nephrol 1996; 7: 472-478.
14. Coda Y, Nishi S, Miyazaki S, Haginoshita S, Sakurabayashi T, Suzuki M, et al. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997; 52: 1096-1101.
15. Gutierrez A, Alvestrand A, Wahren J, Bergström J. Effect of in vivo contact between blood and dialysis membranes on protein catabolism in humans. Kidney Int 1990; 38: 487-494.
16. Parker III TF, Wingard RL, Husni L, Ikizler TA, Parker RA, Hakim RM. Effect of the membrane biocompatibility on nutritional parameters in chronic hemodialysis patients. Kidney Int 1996; 49: 551-556.
17. Locatelli F, Mastrangelo F, Redaelli B, Ronco C, Marcelli D, La Greca G, Orlandini G. and the Italian Cooperative Dialysis Study Group. Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. Kidney Int 1996; 50: 1293-1302.
18. Ifudu O, Feldman J, Friedman EA. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 1996; 334: 420-425.
19. Josephson MA, Fellner SK, Dasgupta A. Improved lipid profiles in patients undergoing high-flux hemodialysis. Am J Kidney Dis 1992; 20: 361-366.
20. Seres DS, Strain GW, Hashim SA, Goldberg IJ, Levin NW. Improvement of plasma lipoprotein profiles during high-flux dialysis. J Am Soc Nephrol 1993; 3: 1409-1415.
21. Ingram AJ, Parbtani A, Churchill DN. Effects of two low-flux cellulose acetate dialysers on plasma lipids and lipoproteins - a crossover trial. Nephrol Dial Transplant 1998; 13: 1452-1457.
22. Held PJ, Port FK, Wolfe RA, Stannard DC, Carroll CE, Daugirdas JT, et al. The dose of hemodialysis and patient mortality. Kidney Int 1996; 50: 550-556.
23. Hakim RM, Held PJ, Stannard DC, Wolfe RA, Port FK, Daugirdas JT, et al. Effect of the dialysis membrane on mortality of chronic hemodialysis patients. Kidney Int 1996; 50: 566-570.
24. Charra B, Calemard E, Ruffet M, Chazot C, Terrat J-C, Vanel T, et al. Survival as an index of adequacy of dialysis. Kidney Int 1992; 41: 1286-1291.
25. Buccianti G, Ravasi B, Cresseri D, Maisonneuve P, Boyle P, Locatelli F. Cancer in patients on renal replacement therapy in Lombardy, Italy. Lancet 1996; 347: 59-60.
26. NKF-DOQI clinical practical guidelines for hemodialysis adequacy. Am J Kidney Dis 1997; 30 (Suppl 2): S15-S66.